Trials / Completed
CompletedNCT04208646
Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis
A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) for the Treatment of Knee Osteoarthritis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Shanghai AbelZeta Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the efficacy and safety of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy
Detailed description
A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells (AlloJoin®) Therapy for Knee Osteoarthritis. This is a multicenter, randomized, double-blinded, phase II clinical trial. Subjects who are with a clinical diagnosis of knee osteoarthritis cartilage defects and will be randomly distributed 1:1:1 to different group after signing the ICF and screening tests. Each group was treated for two cycles. The patients were followed up to 48 weeks after the first treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Mesenchymal progenitor cells | Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use |
| BIOLOGICAL | No mesenchymal progenitor cells | No mesenchymal progenitor cells for intra- articular use |
Timeline
- Start date
- 2020-05-16
- Primary completion
- 2021-06-30
- Completion
- 2023-07-31
- First posted
- 2019-12-23
- Last updated
- 2023-08-01
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04208646. Inclusion in this directory is not an endorsement.